Clinical Trial Search

Primary: Change in Urinary % Monomethyl Arsenic — 2.4; 0.24; -0.06; -3.2 percentage of total urinary arsenic

Primary: Peak Plasma Concentration of 14C-BaP Cmax — 7.07; 1.60 fg [14C]-BaP/mL plasma

Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023

Primary: Percent Change in Biomarker (GLI2 Protein) Levels — 75 percentage decrease

Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg

Primary: Peak Plasma Concentration Cmax — 2.51; 5.68; 13.8; 8.99 fg [14C]-BaP/mL plasma

Primary: Analysis of 14C-Pyronaridine Total Radioactivity in Urine — 0.09; 0.16; 0.60; 0.71 % administered dose

Primary: Mercury Elimination Rate Before Pre-biotic — 48.5 days

Primary: Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment — 16; 5 participants

Primary: Peak Plasma Concentration of 14C-BaP Cmax — 3.69; 1.67; 0.68 fg [14C]-BaP/mL plasma

Primary: Response Rate — 11; 36 Participants

Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml

Primary: Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) — 30; 25; 10…

Primary: Regional Collection of Metabolites and Gut Microbiota — 10 participants with sulfasalazine detected

Primary: Complete Response (CR) Rate — 55; 5; 15 Participants

Primary: Cmax: Maximum Observed Plasma Concentration for Alisertib and Drug-Related Material Following a Single Dose of [^14C]-Alisertib Oral Solution — 2183.3; 2606.7 nanomole…

Primary: Changes in Endocrine Disrupting Chemical (EDC) Levels as Measured by the Post-intervention Value Minus the Baseline Value. — 5.83; 18.43; 56.94; 75.30 ng/ml — p=<0.05

Primary: Sulforaphane Bioavailability Measured in Sequential 12-Hour Urine Samples — 24.8; 11.0; 4.3 micromoles/24 hours — p=<0.001

Primary: Change in the Autism Behavior Inventory, Short Form (ABI-S) — -2.9; -0.8 score on a scale — p=<0.05

Primary: Accuracy Evaluation: The Degree of Agreement (%) of the ACR | U.S. Urine Analysis Test System as Compared to the Comparator Device — 506; 546; 497; 546 Tests

Primary: Aberrant Behavior Checklist (ABC) - Parent Reported Change — -2.4 score on a scale — p=0.56

Primary: Change Sodium Blood Levels — 141.8; 141.2 mmol/L

Primary: Measures of Liver Function: AST and ALT — 36.2; 52; 31.7; 57.86 IU/L

Primary: Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide — 15 Participants

Primary: Differences in Metabolite Concentrations in Urine Between Individuals With Malodor Issues and Age-matched Healthy Controls. — 3.4; 8.6; 0.443; 0.8 uMol/mM creatinine

Primary: Changes of Cytosine Modification in TMPRSS2 (5-mC at cg16371860) by Magnesium Treatment Versus Placebo — 0.007; -0.001; 0.012; -0.002 units on CpG sites — p=<0.05

Primary: Cobalt Chromium Levels — 1.06 micrograms/dl

Primary: Response Rate (RR) — 0; 0; 2; 15 Participants

Primary: Rate of Iron Excretion. — 1.07; 1.69; 1.08 milligrams per day — p=< 0.05

Primary: Numeric Rating Scale for Itch — 6.42; 7.8 score on a scale (0~10)